Effects of Celecoxib and Nordihydroguaiaretic Acid on Puromycin Aminonucleoside-Induced Nephrosis in the Rat

다국어 초록 (Multilingual Abstract)

The selective cyclooxygenase-2 (COX-2) and 5-lipoxygenase (LOX) inhibitors might

inhibit prostaglandin synthesis and reduce proteinuria. The present study was designed

to investigate the anti-proteinuric effects of nordihydroguaiaretic acid (NDGA) as

compared with celecoxib in puromycin aminonucleoside (PAN) nephrosis rats. Fifty

five male Sprague-Dawley rats were divided into 4 groups; A, normal control; B,

PAN group; C, PAN+COX-2 inhibitor (celecoxib) group; and D, PAN+5-LOX inhibitor

(NDGA) group. After induction of PAN nephrosis through repeated injections of PAN

(7.5 and 15 ㎎/100 g body weight), rats were treated with celecoxib, NDGA, or vehicle

for 2 weeks. Twenty four hour urine protein excretions were significantly lower in

PAN+celecoxib and PAN+NDGA groups than in PAN group. Serum creatinine (SCr)

concentrations and 24 hr urine creatinine clearances (CCr) were not significantly

different in the four groups. Electron microscopy showed that podocyte morphology

was changed after the induction of PAN nephrosis and was recovered after celecoxib

or NDGA administration. Celecoxib significantly recovered the expressions of nephrin,

CD2AP, COX-2, and TGF-β. NDGA also recovered TGF-βexpression, but did not

alter the expressions of nephrin, CD2AP and COX-2. The present study suggested

that celecoxib and NDGA might effectively reduce proteinuria in nephrotic syndrome

without impairing renal function.

참고문헌 (Reference)

1 Washizawa K, "Ultrastructural alteration of glomerular anionic sites in nephrotic patients" 7 : 1-5, 1993

2 Suzuki S, "Transcriptional activation of matrix genes by transforming growth factor-beta 1 in mesangial cells" 1 : 229-237, 1993

3 Kollman-Bauerly KA, "The role of eicosanoids in the process of adaptation following massive bowel resection in the rat" 25 : 275-281, 2001

4 Shankland SJ, "The podocyte’s response to injury: role in proteinuria and glomerulosclerosis" 69 : 2131-2147, 2006

5 McKay NG, "The effects of transforming growth factor-beta 1 on mesangial cell fibronectin synthesis: increased incorporation into the extracellular matrix and reduced pI but no effect on alternative splicing" 59 : 211-224, 1993

6 Marchenko HI, "The correction of disorders in arachidonic acid metabolism in coronary spasm of an immune origin" 40 : 81-87, 1994

7 Wang JL, "Selective increase of cyclooxygenase-2 expression in a model of renal ablation" 275 : F613-F622, 1998

8 Poncelet AC, "Regulation of human mesangial cell collagen expression by transforming growth factor-β1" 275 : F458-F466, 1998

9 Ezberci F, "Protective effect of a lipoxygenase inhibitor, nordihydroguaiaretic acid, on the ileal motor disturbances induced by Serratia marcescens endotoxin in rats" 31 : 497-501, 2001

10 Emery P, "Pharmacology, safety data and therapeutics of COX-2 inhibitors, in improved non-steroidal anti-inflammatory drugs, COX-2 enzyme inhibitors" Kluwer 229-241, 1996

11 Cheng H, "Overexpression of cyclooxygenase-2 predispodes to podocyte injury" 18 : 551-559, 2007

12 Anjaneyulu M, "Nordihydroguairetic acid, a lignin prevents oxidative stress and the development of diabetic nephropathy in rats" 72 : 42-50, 2004

13 Hagiwara M, "Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis" 69 : 1146-1152, 2006

14 Arteaga S, "Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid" 98 : 231-239, 2005

15 Liu S, "Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats" 284 : 9-17, 2006

16 Bertram JF, "In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes" 260 : 555-563, 1990

17 Grond J, "Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside" 51 : 277-285, 1984

18 Farquhar MG, "Glomerular permeability: II. ferritin transfer across the glomerular capillary wall in nephrotic rats" 114 : 699-716, 1961

19 Mahan JD, "Glomerular basement membrane anionic charge site change early in aminonucleoside nephrosis" 125 : 393-401, 1986

20 Frenk S, "Experimental nephrotic syndrome induced in rats by aminonucleoside. Renal lesion and body electrolyte composition" 89 : 424-427, 1955

21 Marinides GN, "Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy" 37 : 749-757, 1990

22 Fishman JA, "Effects of the aminonucleoside: puromycin on glomerular epithelial cells in vitro" 118 : 398-407, 1985

23 Blume C, "Effects of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat" 56 : 1770-1778, 1999

24 Cheng HF, "Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension" 62 : 929-939, 2002

25 Salari H, "Comparative effects of indomethacin, acetylenic acids, 15-HETE, NDGA and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets" 13 : 53-60, 1984

26 Furness PN, "Basement membrane charge in human glomerular disease" 150 : 267-278, 1986

27 Tries S, "Antithrombotic and platelet function inhibiting effects of ML3000, a new anti-inflammatory drug with COX/5-LOX inhibitory activity" 51 : 129-134, 2002

28 Furness PN, "An evaluation of experimental models of glomerulonephritis" 75 : 9-22, 1994

29 Wang JL, "A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats" 57 : 2334-2342, 2000